News/ News/ R&D Trials leave Galapagos’ SIK programme looking under the weather Phil Taylor Galapagos, Gilead Sciences, psoriasis, Rheumatoid arthritis, SIK inhibitor, ulcerative colitis 0 Comment Galapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound Share X Trials leave Galapagos’ SIK programme looking under the weather https://pharmaphorum.com/news/trials-leave-galapagos-sik-programme-looking-under-the-weather/